JPH03227937A - Remedy and preventive agent of dermal disease - Google Patents
Remedy and preventive agent of dermal diseaseInfo
- Publication number
- JPH03227937A JPH03227937A JP2018887A JP1888790A JPH03227937A JP H03227937 A JPH03227937 A JP H03227937A JP 2018887 A JP2018887 A JP 2018887A JP 1888790 A JP1888790 A JP 1888790A JP H03227937 A JPH03227937 A JP H03227937A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- remedy
- ntht
- oxygen species
- preventive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003449 preventive effect Effects 0.000 title claims abstract description 9
- 201000010099 disease Diseases 0.000 title abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 4
- 230000002500 effect on skin Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 235000021374 legumes Nutrition 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 14
- 239000001301 oxygen Substances 0.000 abstract description 14
- 229910052760 oxygen Inorganic materials 0.000 abstract description 14
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract description 6
- 244000046052 Phaseolus vulgaris Species 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 230000035876 healing Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- -1 sebum Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006518 acidic stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910001120 nichrome Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野〕
二の発明は皮膚に安全で、各種ス１〜レスに起因する活
性酸素種を非特異的に除去し、内因性及び外因性酸化傷
害に起因する皮膚の疾病の治療及び予防に関するもので
ある、〔従来の技術〕
皮膚は人体最大の臓器であるとともに、随ケの疾患防御
の最前線にある。そのためさまさまな環境要因による変
１ヒを受けやすい７酸ｒヒ的ストレスという面から見る
と、皮膚は絶えず酸素に接触し１、紫外線に暴露され、
また皮脂や薬剤及び化粧品等の光感作物質か存在するた
め、活性酸素種や過酸化脂質を巻き込んだ酸化的反応か
惹起されやすい。それに加え、他臓器と同様に炎症によ
り活性化し、遊走してくる好中球などの食細胞系に由来
する活性酸素種が産出され、上皮の力ならす真皮の側に
も２これらによる皮膚組ｍｔ＊害が加えら机ている。[Detailed Description of the Invention] [Industrial Application Field] The second invention is safe for the skin, non-specifically removes active oxygen species caused by various types of stress, and prevents endogenous and extrinsic oxidative damage. BACKGROUND OF THE INVENTION [Background Art] The skin is the largest organ in the human body and is the first line of defense against many diseases. Therefore, from the perspective of acidic stress, the skin is susceptible to changes caused by various environmental factors.1 The skin is constantly in contact with oxygen, exposed to ultraviolet rays,
Furthermore, since photosensitizers such as sebum, drugs, and cosmetics are present, oxidative reactions involving active oxygen species and lipid peroxides are likely to occur. In addition, reactive oxygen species derived from phagocytic cells such as neutrophils that are activated by inflammation and migrate, similar to other organs, are produced, and the dermis, which is powered by the epithelium, also produces skin tissue mt. *Harm is added to the machine.
このような酸化的ストレスに対し、皮膚にはスーパーオ
キサ、イトシスムターセ、カタラゼ反びグルタチオンバ
ーオキシタ゛−ゼなどの活性酸素種除去作用を有する代
謝系が存在し、活性酸素種のレベルを低下させることに
より、皮膚を防御している。この両者のバランスが崩れ
たときに、皮膚は酸化性組織傷害を受け、各種の病態が
発生すると考えら、ｔする。In response to such oxidative stress, the skin has metabolic systems that remove reactive oxygen species, such as superoxa, istosis mutase, catalase, and glutathione peroxidase, and reduce the level of reactive oxygen species. , protects the skin. It is believed that when the balance between the two is disrupted, the skin suffers oxidative tissue damage and various pathological conditions occur.
この際、外来性に活性酸素種除去剤を辞んた薬剤の投与
により、総括性酸素種除去能を高める二とができわ、は
、臨床面ばかりではなく。In this case, administering a drug that is not a reactive oxygen species scavenger can improve the overall oxygen species scavenging ability, and this is not only useful from a clinical perspective.
予防的にも充分に有意義であると考えられ、る。It is considered to be sufficiently meaningful from a preventive point of view.
しかし投与されたスーパーオキサイドジスムターゼなど
の酵素系の活性酸素除去物質には抗原性や基質特異性、
更には酵素反応生成物として、過酸化水素やハイドロキ
シラジカル等の酸化力の強い物質が産生される。このよ
うに酵素系活性酸素種除去物質による皮Ｓ絹織の治療及
び予防のコントロールは非常に困難である、
〔発明か解決しようとする課題〕
そこで生体適合性かよく、しかも非特異的に活性酸素種
を除去できる物質の開発が急務とされていた。発明者ら
は各種の抗酸化剤による皮膚疾患の治療及び予防効果に
ついて検討しているか、豆類及びその加工品の発酵物中
に生体内で非常に強く活性酸素種を非特異的に除去でき
る物質（ＮＴＨＴ −］ ２３ＥとＮＴＨＴ−１２３Ｎ
）を見いたし、この発明を完成したー［課題を解決する
ための手段〕
すなわち、この発明は豆類及びその加工品の発酵物由来
水溶性物質（ＮＴＩ−ＩＴ−１２３Ｅ）を有効成分とす
る各種皮膚疾患の治療薬及び予防剤ならびに豆類及びそ
の加工品の発酵物由来非水溶性物質（ＮＴＨＴ −１２
３Ｎ）を有効成分とする各種の皮膚疾患の治療及び予防
剤を提案するものである。However, the administered enzymatic active oxygen scavenging substances such as superoxide dismutase have antigenicity and substrate specificity.
Furthermore, substances with strong oxidizing power such as hydrogen peroxide and hydroxyl radicals are produced as enzymatic reaction products. As described above, it is extremely difficult to control the treatment and prevention of skin silk using enzymatic active oxygen species removing substances. [Problem to be solved by the invention] There was an urgent need to develop a substance that could remove oxygen species. The inventors have investigated the therapeutic and preventive effects of various antioxidants on skin diseases, and have investigated the presence of substances in fermented products of beans and their processed products that are highly capable of non-specifically removing active oxygen species in vivo. (NTHT-] 23E and NTHT-123N
), and completed the present invention - [Means for solving the problem] That is, the present invention provides a variety of products containing a water-soluble substance derived from fermented products of beans and their processed products (NTI-IT-123E) as an active ingredient. Therapeutic and preventive agents for skin diseases and water-insoluble substances derived from fermented beans and their processed products (NTHT-12)
The present invention proposes therapeutic and preventive agents for various skin diseases containing 3N) as an active ingredient.
次に二の発明を各種の実施例にしたがって説明する、
（１）火傷スト１ノスに及ぼす影響
ヌードマウス（ＢＡＬＢ／ｃ、 ４週齢、雄）を用いオ
リエンタル固型飼料と殺菌した水道水で飼育した。火傷
ストレスはニクロム線をマウスの背部に接触させ、 １
００Ｖの電流を３秒間通して負荷した、その直後にＮＴ
ＨＴ−１２３Ｅ及びＮをそれぞれ５＋ｎｇをプロピレン
ツリコールに溶解し、火傷部及びその周辺皮膚に塗布し
た、火傷部位の治癒の状態及びそれらの皮膚組織の過酸
化物価をチオバルビッール法で測定し−
た、結果を表１及び第１図に示す５
表１．火傷ストレスに及ぼすＮＴＨＴ−１２３Ｅ及びＮ
の影響実験群 完全治癒期間（日数）
ＮＴＨＴ−］２３Ｅ ６ＮＴＩＩＴ
−１２３Ｎ ５対照
９
ＮＴ１１Ｔ−１２３ＥとＮ処置群の完全治癒期間は表１
に示したように、対照群に較べ、ビで約３３％、Ｎで約
４４％短縮された。また治癒後の皮膚の状態も、病理学
的にはコラ−ケンの増加等か認められるが、肉眼的には
対照群よりもＮＴＩ＋Ｔ−１２３Ｅ及びＮ共にケロイド
も少なく、極めて良好であった。Next, the second invention will be explained according to various examples. bred. Burn stress was achieved by touching the back of the mouse with a nichrome wire.
A current of 00V was applied for 3 seconds, and immediately after that, the NT
5+ng of each of HT-123E and N were dissolved in propylene glycol and applied to the burn area and surrounding skin. The state of healing of the burn area and the peroxide value of the skin tissue were measured using the thiobarbir method. The results are shown in Table 1 and Figure 1.5 Table 1. Effect of NTHT-123E and N on burn stress
Effect experimental group Complete healing period (days) NTHT-]23E 6NTIIT
-123N 5 control
9 Complete healing time for NT11T-123E and N treatment groups is shown in Table 1.
As shown in , the time was shortened by about 33% in Bi and by about 44% in N compared to the control group. In addition, the condition of the skin after healing was pathologically observed as an increase in collagen, but macroscopically it was extremely good with fewer keloids in both NTI+T-123E and N than in the control group.
また、火傷ストレス負荷後の火傷部位及びその周辺の経
口的な過酸化物価は第１図に示したように、 ＮＴＨＴ
−１２：”、Ｅ及びＮ共に対照群に較べて有意に抑制さ
れていた。しかし１、ＮＴＨＴ１２３ＥとＮとを比較す
ると、過酸ｆヒ物価の抑制に若干のタイムラグか認めら
れた３これはＮＴＩＩＴ’−１２：”、ＥとＮの経皮的
吸収率の差であろうど考えられる。In addition, as shown in Figure 1, the oral peroxide value at the burn site and its surroundings after applying burn stress is NTHT.
-12: Both E and N were significantly suppressed compared to the control group. However, when comparing 1. NTHT123E and N, a slight time lag was observed in the suppression of peracid f levels. 3. NTIIT'-12:'', this is thought to be due to the difference in percutaneous absorption rate of E and N.
二九らのことか１５ 、 ＮＴＨＴ ］、２３Ｅ及び
Ｎは経皮的に吸収され、炎症誘発後の周辺組織の変性壊
死進行の要因になっている活性酸素種を除去し、火傷部
及びその周辺の皮膚組織の酸１ヒ錫害を防止することに
より、火傷の治癒を促進していると考えられる。Niku et al. [15], 23E and N are absorbed transdermally, remove reactive oxygen species that are a factor in the progression of degenerative necrosis in surrounding tissues after induction of inflammation, and are effective in burning areas and their surrounding areas. It is thought that it promotes the healing of burn wounds by preventing the damage caused by tin acid to the skin tissue.
（２）紫外線ストレスに及ぼす影響
２７歳の健康な男性の背部皮膚に中波紫外線（２ＦＩＯ
−３２０ｎｍ）２０００−３０００ｕｖ／ｃｎｆを６０
秒間照射し２日焼は時の皮膚の炎症を誘発させた。(2) Effects on UV stress
-320nm) 2000-3000uv/cnf 60
After irradiation for 2 seconds, tanning induced inflammation of the skin.
〜ＴＩＩＴ −１２３ＥとＮＴＨＴ−１２３Ｎをそれぞ
れ１２ｍＦ、／ｍ Ｑになるようにプロピレンクリコー
ルに溶かし、紫外線照射の直後、紫欠線暴露部に塗布し
た。~TIIT-123E and NTHT-123N were each dissolved in propylene glycol to a concentration of 12 mF/m Q, and immediately after UV irradiation, they were applied to the exposed area of the purple line.
紫外線による炎症時の体表面温度と肉眼による色差を指
標とし、て、その効果を測定した。The effects were measured using body surface temperature and visual color difference during inflammation caused by ultraviolet rays as indicators.
その結果を第２図と表２に示す。The results are shown in FIG. 2 and Table 2.
表２２４時間後の皮膚炎症度
−
紫外線照射４時間後め皮膚表面温度の上昇率は第２図に
示したように、対照に較べて、それぞれＮＴＨＴ −１
２３Ｅで１２．５％、 ＮＴＨＴ−１２３Ｎでは６６．
７％抑制さ戯ていた。しかし、２４時間後では１表２に
示したように、 ＮＴＨＴ −＋２：’、ＥとＮに顕著
な差異は認めＬ３れず、再考′共にｆｆｌ膚表面表面温
度意に低下しており その時の炎症反応もほとんど認め
ら、ｔ１５なかった、これらのように、 ＮＴＨｒ−ｔ
２３ＥどＮは共に経皮的に吸収され、紫外線暴露により
誘発される活性酸素種を生体内で充分に除去でき、活性
酸素種に起因するどされている炎症を抑制できると考え
られる。Table 2: Degree of skin inflammation after 24 hours - 4 hours after UV irradiation, the rate of increase in skin surface temperature was NTHT -1 compared to the control, as shown in Figure 2.
12.5% for 23E and 66% for NTHT-123N.
He was playing with 7% restraint. However, after 24 hours, as shown in Table 1, there was no significant difference between NTHT -+2:', E and N, and the skin surface temperature of both of them decreased significantly, indicating the inflammation at that time. Almost no reaction was observed, and there was no t15, as in these cases, NTHr-t
Both 23E and N are absorbed transdermally and are thought to be able to sufficiently remove in vivo the active oxygen species induced by exposure to ultraviolet rays, thereby suppressing inflammation caused by the active oxygen species.
（３）日焼げによる炎症に及ぼす影響
ＮＴＨＴ −１，２３Ｅを２０ｍｇ／ｍ（１，どなるよ
うにプロピレンクリコールに溶解し７．全身に塗布した
後夏期の直射日光に全身を晒した、二〇）状態を約３０
分間保持し、た後、１０分間水浴し、再度ＮＴＩＩＴ−
１２３Ｅを全身に塗布し、た、二の過程を合計５時間続
けた後１日焼は及び炎症の度合を肉眼及び自己申告によ
り判定し、た。(3) Effects on inflammation caused by sunburn NTHT-1,23E was dissolved in propylene glycol at 20 mg/m (1. 〇) Condition about 30
After holding for 10 minutes, take a water bath for 10 minutes, and then use NTIIT-
After applying 123E to the whole body and continuing the steps 1 and 2 for a total of 5 hours, the degree of sunburn and inflammation was determined visually and by self-report.
この結果 製表３に示す。As a result Table 3 shows the results.
■ 試料 試料： ＮＴＨＴ ２３Ｅ 濃度： ２０ｍＦＣ／ｍｌ プロピレングリコ ル 試験 場所＝西伊豆 期間：２日 １９８８ ７−１０） 検体 ぬった、 ｅ、ｆは、何もぬっていない。■ sample Sample: NTHT 23E Concentration: 20mFC/ml propylene glyco le test Location = Nishiizu Duration: 2 days 1988 7-10) specimen I got it, Nothing has been sewn on e and f.
通常被験者らは市販の各種オ（ルを塗布していても、経
験的に夏期の直射日光に長時間皮膚を暴露させると、火
ｒｉ＆性水泡や非常な痛みを感じる事を知っている し
、かじ、表３に示したように、 ＮＴＩ（Ｔ−１２３Ｅ
を塗布した場き。Normally, even if the subjects applied various commercially available oils, they knew from experience that if their skin was exposed to direct sunlight in the summer for a long time, they would experience flare-ups, blisters, and severe pain. However, as shown in Table 3, NTI (T-123E
When applied.
日焼けはするものの、炎症による痛みはほとんど感じら
九なかった。この結果は前記実施例（２）と非常によ・
く類似し、ており、自然光中の紫外線に暴露することに
より惹起される活性酸素種をＮＴ）ＩＴ−１２３Ｆが非
特異的に除去したと考えられる。また、こ慣らの実験に
よる副作用は全（認められなかったー
〔発明の効果〕
以上のごとく、この発明の豆類文びその加工品の発酵物
由来非特異的活性酸素種消去物質（ＮＴＨＴ−’１２３
Ｅ及びＮ）は経皮的に吸収され、種々のス１−レスによ
り誘発された活性酸素種による皮膚疾患の治療及び予防
に非常に有効である。なおこの発明の実施例で用いてい
るプロピレンダリコールはこの発明を説明するだめの、
７／、のものであり、 ＮＴＨＴ−１２３Ｅ及ヒｌｌｌ
ノほかに、種々の調合剤は通常のいすＩｑ、の薬剤的又
は美容的に許容される不活性添加物又は薬剤的に活性な
添加物も含むことができる。Although I got sunburned, I felt almost no pain due to inflammation. This result is very different from Example (2) above.
It is thought that NT)IT-123F nonspecifically removed active oxygen species induced by exposure to ultraviolet rays in natural light. In addition, no side effects were observed in the experiments conducted by Kojira et al. [Effects of the Invention] As described above, the non-specific active oxygen species scavenging substance (NTHT-') derived from fermented legumes and processed products of the present invention 123
E and N) are absorbed transdermally and are very effective in the treatment and prevention of skin diseases caused by reactive oxygen species induced by various stressors. Note that the propylene dalicol used in the examples of this invention is of no use in explaining this invention.
7/, NTHT-123E and Hill
Besides, the various formulations can also contain the usual pharmaceutically or cosmetically acceptable inert additives or pharmaceutically active additives.
更にこの発明の実施例中の塗布量及び塗布方法などはこ
の発明を説明するためだけのものであり、塗布用量及び
塗布方法などについて特に限定するものではない−Furthermore, the coating amount and coating method in the examples of this invention are only for illustrating the present invention, and are not intended to particularly limit the coating amount and coating method.
第１図は火爆ストレス負荷後の・ｋ、傷部位及びその周
辺の経口的な過酸化物価を示す図で、第２図は紫外線照
射４時間後の皮膚表面温度の上昇率を示す図である。Figure 1 shows the oral peroxide value at the wound site and its surroundings after applying firebomb stress, and Figure 2 shows the rate of increase in skin surface temperature after 4 hours of ultraviolet irradiation. .
Claims (2)
ＴＨＴ−１２３Ｅ）を有効成分とする各種皮膚疾患の治
療及び予防剤。(1) Water-soluble substances (N
A therapeutic and preventive agent for various skin diseases containing THT-123E) as an active ingredient.
ＮＴＨＴ−１２３Ｎ）を有効成分とする各種皮膚疾患の
治療及び予防剤。(2) Water-insoluble substances derived from fermented legumes and their processed products (
A therapeutic and preventive agent for various skin diseases containing NTHT-123N) as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018887A JPH03227937A (en) | 1990-01-31 | 1990-01-31 | Remedy and preventive agent of dermal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018887A JPH03227937A (en) | 1990-01-31 | 1990-01-31 | Remedy and preventive agent of dermal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03227937A true JPH03227937A (en) | 1991-10-08 |
Family
ID=11984079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018887A Pending JPH03227937A (en) | 1990-01-31 | 1990-01-31 | Remedy and preventive agent of dermal disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03227937A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Skin-bleaching agent for peroral administration and skin-bleaching food |
| CN104474469A (en) * | 2014-12-01 | 2015-04-01 | 国家电网公司 | Method for preparing electric injury paste preparation |
-
1990
- 1990-01-31 JP JP2018887A patent/JPH03227937A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Skin-bleaching agent for peroral administration and skin-bleaching food |
| CN104474469A (en) * | 2014-12-01 | 2015-04-01 | 国家电网公司 | Method for preparing electric injury paste preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5042209B2 (en) | Cosmetic treatment with nitric oxide, apparatus for performing the treatment, and method for manufacturing the same | |
| CA1166575A (en) | Therapeutic dimethyl sulfoxide composition and methods of use | |
| CA1332570C (en) | Method for reducing skin irritation associated with drug/penetration enhancer compositions | |
| Calzavara-Pinton et al. | A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications | |
| JP4745608B2 (en) | Skin treatment using phosphoric acid derivatives of electron transfer agents | |
| HU213450B (en) | Gel contains gelatin and process for producing it | |
| CA2105313A1 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
| JP2012509870A (en) | Perfluorocarbon gel formulation | |
| AU2016328549B2 (en) | Hydrophilic gel for topical delivery of 5-aminolevulinic acid | |
| PT822816E (en) | DERMATOLOGICAL PREPARATION AND METHOD FOR TREATING ACTINAL CERATOSES | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| US20120083452A1 (en) | Topical Anesthetic Uses of Szeto-Schiller Peptides | |
| EP0531495A1 (en) | Therapeutic and cosmetic compositions for treatment of skin. | |
| BR102018002462A2 (en) | kit, topical composition, film and its uses | |
| US20080102089A1 (en) | Topical and transdermal treatments using urea formulations | |
| RU2470640C1 (en) | Agent for treating inflammatory oral diseases and method of treating inflammatory oral diseases | |
| EP1063981A1 (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
| JPH03227937A (en) | Remedy and preventive agent of dermal disease | |
| RU2702347C2 (en) | Treating or preventing seborrheic keratosis using artemisinin and derivatives thereof | |
| CN116348099A (en) | Topical formulations | |
| RU2661861C1 (en) | Method for treatment of chronic mechanical trauma of the oral mucosa in patients suffering with insulin-dependent diabetes mellitus | |
| WO2020175131A1 (en) | External preparation for vascular abnormality treatment | |
| Saleh et al. | Assessment of Plasma Malondialdehyde in Acne Patients on Isotretinoin Therapy | |
| JP2013542922A (en) | Treatment of fungal infection | |
| JP2008044916A (en) | Bedsore-treating agent |